X-ray Crystallographic Analysis of α-Ketoheterocycle Inhibitors Bound to a Humanized Variant of Fatty Acid Amide Hydrolase

被引:52
作者
Mileni, Mauro [3 ]
Garfunkle, Joie [1 ]
Ezzili, Cyrine [1 ]
Kimball, F. Scott [1 ]
Cravatt, Benjamin F. [2 ]
Stevens, Raymond C. [1 ,3 ]
Boger, Dale L. [1 ]
机构
[1] Scripps Res Inst, Dept Chem, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA
[2] Scripps Res Inst, Dept Physiol Chem, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA
[3] Scripps Res Inst, Dept Mol Biol, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA
基金
美国国家卫生研究院;
关键词
TRIFLUOROMETHYL KETONE INHIBITORS; HUMAN NEUTROPHIL ELASTASE; ENDOCANNABINOID SYSTEM; THERAPEUTIC TARGET; MOLECULAR CHARACTERIZATION; KETOOXAZOLE INHIBITORS; ANANDAMIDE HYDROLYSIS; SUBSTRATE-SPECIFICITY; CANNABINOID RECEPTOR; EXCEPTIONALLY POTENT;
D O I
10.1021/jm9012196
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Three cocrystal X-ray Structures of the alpha-ketoheterocycle inhibitors 3-5 bound to a humanized variant of fatty acid amide hydrolase (FAAH) are disclosed and comparatively discussed alongside those of 1 (OL-135) and its isomer 2. These five X-ray Structures systematically probe each of the three active site regions key to substrate or inhibitor binding: (1) the conformationally mobile acyl chain-binding pocket and membrane access channel responsible for fatty acid amide substrate and inhibitor acyl chain binding, (2) the atypical active site catalytic residues and surrounding oxyanion hole that covalently binds the core of the alpha-ketoheterocycle inhibitors captured as deprotonated hemiketals mimicking the tetrahedral intermediate of the enzyme-catalyzed reaction, and (3) the cytosolic port and its uniquely important imbedded ordered water molecules and a newly identified anion binding site. The detailed analysis of their key active site interactions and their implications on the interpretation of the available structure-activity relationships are discussed providing important insights for future design.
引用
收藏
页码:230 / 240
页数:11
相关论文
共 94 条
[1]  
Abouab-Dellah AB, 2004, Patent, Patent No. [WO 2004/099176, 2004099176]
[2]  
ABOUABDELLAH A, 2007, Patent No. 2007027141
[3]  
ABOUABDELLAH A, 2005, Patent No. 2005070910
[4]  
ABOUABDELLAH A, 2005, Patent No. 2005077898
[5]   Enzymatic pathways that regulate endocannabinoid signaling in the nervous system [J].
Ahn, Kay ;
McKinney, Michele K. ;
Cravatt, Benjamin F. .
CHEMICAL REVIEWS, 2008, 108 (05) :1687-1707
[6]   Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders [J].
Ahn, Kay ;
Johnson, Douglas S. ;
Cravatt, Benjamin F. .
EXPERT OPINION ON DRUG DISCOVERY, 2009, 4 (07) :763-784
[7]   Discovery and Characterization of a Highly Selective FAAH Inhibitor that Reduces Inflammatory Pain [J].
Ahn, Kay ;
Johnson, Douglas S. ;
Mileni, Mauro ;
Beidler, David ;
Long, Jonathan Z. ;
McKinney, Michele K. ;
Weerapana, Eranthie ;
Sadagopan, Nalini ;
Liimatta, Marya ;
Smith, Sarah E. ;
Lazerwith, Scott ;
Stiff, Cory ;
Kamtekar, Satwik ;
Bhattacharya, Keshab ;
Zhang, Yanhua ;
Swaney, Stephen ;
Van Becelaere, Keri ;
Stevens, Raymond C. ;
Cravatt, Benjamin F. .
CHEMISTRY & BIOLOGY, 2009, 16 (04) :411-420
[8]   Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity [J].
Ahn, Kyunghye ;
Johnson, Douglas S. ;
Fitzgerald, Laura R. ;
Liimatta, Marya ;
Arendse, Andrea ;
Stevenson, Tracy ;
Lund, Eric. T. ;
Nugent, Richard A. ;
Nomanbhoy, Tyzoon K. ;
Alexander, Jessica P. ;
Cravatt, Benjamin F. .
BIOCHEMISTRY, 2007, 46 (45) :13019-13030
[9]   The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases [J].
Alexander, Jessica P. ;
Cravatt, Benjamin F. .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2006, 128 (30) :9699-9704
[10]   Mechanism of carbamate inactivation of FAAH: Implications for the design of covalent inhibitors and in vivo functional probes for enzymes [J].
Alexander, JP ;
Cravatt, BF .
CHEMISTRY & BIOLOGY, 2005, 12 (11) :1179-1187